Skip to main content
. Author manuscript; available in PMC: 2021 Mar 1.
Published in final edited form as: Clin Cancer Res. 2020 Jul 10;26(17):4651–4660. doi: 10.1158/1078-0432.CCR-19-4112

Figure 4. Frequency of major pathway alterations and tumor mutational burdens.

Figure 4.

(A) Frequency of major pathway alterations with no significant differences between AFR (solid) and EUR (shadow) in localized or metastatic PCa samples, including DNA repair pathway genes, RAS/MAPK pathway genes and WNT pathway genes in which alterations were detected in the Foundation cohort. Gene alteration rates are shown as side-by-side bar charts consisting of a total of four color-coded alteration classes. If the alteration frequency for a gene was 0, it was omitted in the dataset. (B) Tumor mutational burdens (TMB) in both localized and metastatic PCa (localized: n_AFR = 124, n_EUR = 852; metastatic: n_AFR = 202, n_EUR = 1695). TMBs were computed as the percentage of patients within the cohort with respect to the number of mutations detected (0~100). No significant difference was found between AFR (blue) and EUR (orange) populations.